Targeting survivin in cancer: the cell-signalling perspective

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Survivin is a critical anticancer target, widely expressed across various cancers.
• The intricate functional regulation of survivin remains incompletely understood.
• Survivin's therapeutic modulation is influenced by interactions with key cell-signaling pathways.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in the pharmacological modulation of survivin.
• To explore the role of cell-signaling pathways in survivin regulation.
• To discuss the development of antisurvivin therapeutics and their potential in drug-resistant cancers.

Main Methods:

• Literature review of recent studies on survivin regulation and therapeutic strategies.
• Analysis of the interplay between survivin and various cell-signaling pathways (e.g., HIF-1α, PI3K/AKT, ERK, p53, EGFR, VEGF).
• Discussion of current antisurvivin therapeutic approaches.

Main Results:

• Survivin's function is intricately linked to multiple signaling cascades, including those involving hypoxia-inducible factor 1-alpha (HIF-1α), heat shock protein 90 (HSP90), phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK), tumor suppressor genes (p53, PTEN), oncogenes (Bcl-2, Ras), and growth factors (EGFR, VEGF).
• Pharmacological targeting of these pathways offers potential for modulating survivin activity.
• Emerging antisurvivin therapeutics show promise in preclinical and clinical settings.

Conclusions:

• Targeting survivin through modulation of associated cell-signaling pathways is a promising strategy for cancer therapy.
• Antisurvivin therapeutics represent a developing field with potential to overcome drug resistance.
• Further research into survivin's complex regulatory network is essential for optimizing cancer treatment.